Centessa Pharmaceuticals plc ADR (CNTA) poses a Brand-New Opportunity for Investors with beta value of 1.54

As on Thursday, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) started slowly as it slid -3.44% to $14.87, before settling in for the price of $15.40 at the close. Taking a more long-term approach, CNTA posted a 52-week range of $6.95-$18.97.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.97%. This publicly-traded company’s shares outstanding now amounts to $131.66 million, simultaneously with a float of $90.14 million. The organization now has a market capitalization sitting at $1.96 billion. At the time of writing, stock’s 50-day Moving Average stood at $16.83, while the 200-day Moving Average is $12.96.

Centessa Pharmaceuticals plc ADR (CNTA) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Centessa Pharmaceuticals plc ADR’s current insider ownership accounts for 31.53%, in contrast to 51.06% institutional ownership. Preceding that transaction, on Dec 26 ’24, Company’s Chief Business Officer sold 10,000 for 17.04, making the whole transaction’s value amount to 170,399. This particular insider is now the holder of 183,266 in total.

Centessa Pharmaceuticals plc ADR (CNTA) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.

Centessa Pharmaceuticals plc ADR’s EPS increase for this current 12-month fiscal period is 2.97% and is forecasted to reach -1.55 in the upcoming year.

Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators

Let’s observe the current performance indicators for Centessa Pharmaceuticals plc ADR (CNTA). It’s Quick Ratio in the last reported quarter now stands at 21.52. The Stock has managed to achieve an average true range (ATR) of 1.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 283.33.

In the same vein, CNTA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.53, a figure that is expected to reach -0.42 in the next quarter, and analysts are predicting that it will be -1.55 at the market close of one year from today.

Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)

Through scrutinizing the latest numbers posted by the [Centessa Pharmaceuticals plc ADR, CNTA], it can be observed that its last 5-days Average volume of 0.41 million was lower the volume of 0.54 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 16.76% While, its Average True Range was 1.07.

Raw Stochastic average of Centessa Pharmaceuticals plc ADR (CNTA) in the period of the previous 100 days is set at 41.18%, which indicates a major rise in contrast to 12.08% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 52.99% that was lower than 61.11% volatility it exhibited in the past 100-days period.